Establishments primarily engaged in the production of bacterial and virus vaccines, toxoids, and analogous products (such as allergenic extracts), serums, plasmas, and other blood derivatives for human or veterinary use, other than in vitro and in vivo diagnostic substances. Included in this industry are establishments primarily engaged in the production of microbiological products for other uses. Establishments primarily engaged in manufacturing in vitro and in vivo diagnostic substances are classified in Industry 2835.
Agar culture media, except in vitro and in vivo
Aggressins, except in vitro and in vivo
Allergenic extracts, except in vitro and in vivo
Allergens
Anti-hog-cholera serums
Antigens
Antiserums
Antitoxins
Antivenin
Bacterial vaccines
Bacterins, except in vitro and in vivo
Bacteriological media, except in vitro and in vivo
Biological and allied products: antitoxins, bacterins, vaccines, viruses,
Blood derivatives, for human or veterinary use, except in vitro and
Coagulation products
Culture media or concentrates, except in vitro and in vivo
Diphtheria toxin
Hematology products, except in vitro and in vivo reagents
Plasmas
Pollen extracts, except in vitro and in vivo
Serobacterins
Serums, except in vitro and in vivo
Toxins
Toxoids except in vitro and in vivo
Tuberculins
Vaccines
Venoms
Viruses
A review and comparison of financial performance of privately-help companies in specified SIC/NAICS industry segment, using industry standard benchmarks.
Answeres comes easily with Industrius CFO. Review ROI, sales per employee, profit margins of the top 10%, top 25% and more, to identify areas of concern and opportunity. Examine “what if scenarios and P&L impact of reducing costs or adding revenue.
It takes only five minutes to enter your data and produce a concise profile of your company’s fiscal state, including critical business ratios focusing on liquidity, profitability, asset efficiency, and growth.